InvestorsHub Logo
Followers 35
Posts 6969
Boards Moderated 1
Alias Born 04/04/2020

Re: ggwpq post# 364671

Monday, 12/27/2021 1:24:22 PM

Monday, December 27, 2021 1:24:22 PM

Post# of 427976
ggwpq, Your not wrong. PCSK9 inhibitors also aren't cheap. Vascepa is going to gain traction in the CVD market. Like you said, the math is on our side. Not that I think this will happen, but insurance formularies should be changed. Lipid altering drugs should be listed separately from CVD drugs.
Sleven,
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News